CIK 0000875320 · Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 043039129
- Phone
- 6173416393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-17 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale 10b5-1 | −2,437 | $489.46 | $1.2M | 9,668 |
| 2026-02-17 | Bozic Carmen EVP and CMO | Grant or award | +5,375 | 43,428 | ||
| 2026-02-17 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −1,912 | $483.75 | $925K | 41,516 |
| 2026-02-17 | Biller Jonathan EVP and Chief Legal Officer | Grant or award 10b5-1 | +4,135 | 20,973 | ||
| 2026-02-17 | Biller Jonathan EVP and Chief Legal Officer | Shares withheld for taxes 10b5-1 | −1,505 | $483.75 | $728K | 19,468 |
| 2026-02-17 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −2,476 | $489.46 | $1.2M | 16,992 |
| 2026-02-17 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Grant or award 10b5-1 | +4,962 | 25,105 | ||
| 2026-02-17 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Shares withheld for taxes 10b5-1 | −1,530 | $483.75 | $740K | 23,575 |
| 2026-02-17 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −2,031 | $489.46 | $994K | 21,544 |
| 2026-02-17 | Ambrose Kristen SVP & Chief Accounting Officer | Grant or award 10b5-1 | +1,809 | 10,543 | ||
| 2026-02-17 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes 10b5-1 | −598 | $483.75 | $289K | 9,945 |
| 2026-02-17 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −1,557 | $489.46 | $762K | 8,388 |
| 2026-02-13 | WAGNER CHARLES F JR EVP, CO & FO | Shares withheld for taxes | −4,565 | $487.76 | $2.2M | 43,715 |
| 2026-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −3,804 | $487.76 | $1.9M | 47,632 |
| 2026-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −1,500 | $499.99 | $750K | 46,132 |
| 2026-02-13 | Sachdev Amit EVP Chief Patient & Ext Af Off | Shares withheld for taxes | −3,548 | $487.76 | $1.7M | 65,393 |
| 2026-02-13 | McKechnie Duncan EVP, Chief Commercial Officer | Shares withheld for taxes | −2,283 | $487.76 | $1.1M | 19,528 |
| 2026-02-13 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −13,041 | $487.76 | $6.4M | 133,487 |
| 2026-02-13 | Bunnage Mark E. EVP, Chief Scientific Officer | Shares withheld for taxes | −2,283 | $487.76 | $1.1M | 10,631 |
| 2026-02-13 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −3,804 | $487.76 | $1.9M | 38,053 |
Page 7 of 10 · 182 trades